AUTHOR

Dr Mike Tubbs

For decades, Dr Mike Tubbs worked on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing. Knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development.

A UK-listed multinational engineer with strong growth and rising dividends
Share tips

A UK-listed multinational engineer with strong growth and rising dividends

Spirax-Sarco is a world-leading engineer making consistent progress in three niche markets, with an order book at an all-time high.
29 Jun 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Raytheon Technologies: a safe stock for an unsafe world
Share tips

Raytheon Technologies: a safe stock for an unsafe world

Defence spending is set to soar – that should be good news for aerospace heavyweight Raytheon Technologies.
26 Apr 2022
Veterinary medicine stocks: the firms keeping your pet healthy
Share tips

Veterinary medicine stocks: the firms keeping your pet healthy

Pet ownership has grown due to the pandemic. That’s good news for animal health stocks, says Dr Mike Tubbs
11 Mar 2022
Adobe: a growth stock with a wide moat
Share tips

Adobe: a growth stock with a wide moat

Adobe already dominates the creative industries – now it’s expanding into ecommerce
22 Feb 2022
The best vaccine-makers’ stocks to buy now
Biotech stocks

The best vaccine-makers’ stocks to buy now

The rapid development of Covid-19 vaccines has already saved many lives and made huge profits for a few pharmaceutical firms. Investors should keep an…
13 Jan 2022
Molten Ventures: invest in digital technology with this venture capitalist
Share tips

Molten Ventures: invest in digital technology with this venture capitalist

Molten Ventures offers investors access to fast-growing unlisted companies across Europe
31 Dec 2021
The nifty nine: a portfolio of stocks to buy and hold forever
Share tips

The nifty nine: a portfolio of stocks to buy and hold forever

A diverse range of stocks you can buy and keep forever should be a core part of any equity portfolio, says Dr Mike Tubbs. He selects his nine favourit…
12 Nov 2021
Duke Royalty: a princely return for income investors
Share tips

Duke Royalty: a princely return for income investors

Britain’s only listed royalty-finance company chooses its clientele wisely, making it a compelling income play
2 Nov 2021
University spin-outs: where to find companies involved in cutting-edge science
Share tips

University spin-outs: where to find companies involved in cutting-edge science

Universities are innovation incubators and often launch businesses involved in fast-growing fields ranging from biotechnology to artificial intelligen…
24 Sep 2021
Games Workshop: real profits from fantasy games
Share tips

Games Workshop: real profits from fantasy games

Games Workshop, a long-established maker of wargames, has enormous potential for further growth.
31 Aug 2021
A great leap forward in the war against Alzheimer’s disease
Biotech stocks

A great leap forward in the war against Alzheimer’s disease

The approval of the first drug to treat the neurodegenerative disease in 18 years will galvanise research in the entire subsector, says Dr Mike Tubbs.…
16 Jul 2021
How to invest in biotechnology: the healthcare sector’s high-growth area
Biotech stocks

How to invest in biotechnology: the healthcare sector’s high-growth area

Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment str…
14 May 2021
Merck: the good value biotech stock that has cornered the cancer market
Share tips

Merck: the good value biotech stock that has cornered the cancer market

Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.
27 Apr 2021
Scientific-instrument companies are a global success – here's how to play them
Share tips

Scientific-instrument companies are a global success – here's how to play them

Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…
26 Mar 2021
Mpac Group: making steady profits from premium packaging
Share tips

Mpac Group: making steady profits from premium packaging

Mpac Group’s automated packaging machines are sold to blue-chip clients in more than 80 countries worldwide. Dr Mike Tubbs looks at the company's pot…
24 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
Biotech stocks

Vanquishing the virus: the race to make vaccines for Covid-19

The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Novo Nordisk: Denmark’s dominant drug maker
Share tips

Novo Nordisk: Denmark’s dominant drug maker

Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.
4 Nov 2020
How to profit from the development of new auto-immune disease drugs
Biotech stocks

How to profit from the development of new auto-immune disease drugs

Some debilitating conditions are caused by the body’s defence mechanism going awry. Dr Mike Tubbs appraises a key subsector of the pharmaceuticals mar…
29 Oct 2020
Lessons for investors from Big Tech's previous golden era
Tech stocks

Lessons for investors from Big Tech's previous golden era

The forerunners of today's tech stock titans dominated the 1960s and 1970s. Former Xerox senior manager Dr Mike Tubbs was there and explains what inve…
16 Oct 2020
Healthy profits: how to make money from investing in medical technology
Share tips

Healthy profits: how to make money from investing in medical technology

There’s far more to the health sector than whizzy new pills, says Dr. Mike Tubbs. He reviews the latest developments in areas ranging from robotic sur…
25 Jun 2020
Lockheed Martin: the world’s best defence stock
Share tips

Lockheed Martin: the world’s best defence stock

Lockheed Martin is the industry’s most diversified top-quality company and a robust pick in tough times.
22 Jun 2020
Where to find "ten-bagger" stocks – the market's Holy Grail
Share tips

Where to find "ten-bagger" stocks – the market's Holy Grail

“Ten-baggers,” stocks with the potential to rise tenfold, are rare but not impossible to find. Dr Mike Tubbs explores their key characteristics and su…
11 Jun 2020
Gilead's anti-viral expertise will stand it well
Share tips

Gilead's anti-viral expertise will stand it well

There is far more to biotech giant Gilead Sciences than its potential treatment for Covid-19; it has expertise in anti-virals against a wide range of …
14 Apr 2020
This high quality engineering firm will filter profits to investors
Share tips

This high quality engineering firm will filter profits to investors

Porvair, a maker of high-tech filtration systems, is an excellent long-term pick for your investment portfolio.
4 Mar 2020
Secret sauce: the key to serial innovation and profit growth
Share tips

Secret sauce: the key to serial innovation and profit growth

Why do some companies fizzle out and fade away while others build on a strong start? Dr Mike Tubbs looks at the key factors behind sustainable success…
5 Dec 2019
Stocks that offer two sectors for the price of one
Share tips

Stocks that offer two sectors for the price of one

There are several excellent companies that dabble in two very different markets. Dr Mike Tubbs highlights the ones worth considering now.
26 Sep 2019
How stem cells are changing the face of medicine
Share tips

How stem cells are changing the face of medicine

We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs exp…
26 Jul 2019
Engineering profits: the British industrial champions to buy now
Share tips

Engineering profits: the British industrial champions to buy now

Move over, Germany and Sweden. There are several world-class UK engineers in profitable niches supplying a vast array of industries with vital equipme…
20 Jun 2019
Swedish engineer Hexagon is in excellent shape
Share tips

Swedish engineer Hexagon is in excellent shape

This Swedish engineer has been overshadowed by bigger local peers, but is well worth a look
12 Jun 2019
Look for profits with Regeneron
Features

Look for profits with Regeneron

Regeneron, a US biotech company, specialises in treating eye diseases. But it’s far from a one-trick pony.
15 May 2019
Where to find and how to invest in founder-managed firms
Share tips

Where to find and how to invest in founder-managed firms

Companies that are set up and then run by the same person for a long time tend to be lucrative investments. Dr Mike Tubbs explains why, how to find fo…
2 May 2019
Diploma qualifies for your portfolio
Share tips

Diploma qualifies for your portfolio

This British mid-cap is a successful global player with plenty of room for expansion, says Dr Mike Tubbs.
16 Apr 2019
Immunotherapy: new hope in the battle against cancer
Share tips

Immunotherapy: new hope in the battle against cancer

Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors …
4 Apr 2019
Alexion: a rare opportunity in biotech
Share tips

Alexion: a rare opportunity in biotech

Alexion focuses on diseases that affect only a tiny proportion of the population – a lucrative niche.
3 Apr 2019
Illumina: shedding light on genetics
Share tips

Illumina: shedding light on genetics

Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.
6 Mar 2019